Pfizer Reports Strong Q4 Earnings But Faces Uncertain Market Sentiment

The pharmaceutical giant beat revenue and earnings estimates, yet its stock remains flat as challenges loom in 2025.

Pfizer reported Q4 2024 revenue of $17.8 billion, a 22% year-over-year increase, and adjusted earnings per share of $0.63, both exceeding Wall Street expectations.
Full-year 2024 revenue reached $63.6 billion, up 7% from 2023, driven by strong sales of key products like Vyndaqel, Eliquis, and Paxlovid.
Despite the earnings beat, Pfizer's stock performance has been lackluster, reflecting investor concerns over declining COVID-19 product revenues and future growth prospects.
The company reaffirmed its 2025 guidance, projecting revenues between $61 billion and $64 billion, while targeting $4.5 billion in cost savings by year-end 2025.
Challenges include Medicare price negotiations, competition in the GLP-1 weight-loss market, and patent expirations, alongside efforts to integrate its $43 billion Seagen acquisition.